drugset

drugset / Trial / NCT00237172

Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)

NCT00237172 ↗

Phase 2 Completed 72 enrolled Novartis Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This is a extension study of CSTI571B1201 study

Timeline

Start: 2002-09
Primary completion: 2005-07
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	400 mg	—

Indications